Wellington Management

Activity in this selectionBiotech

By stage

Series A3

Series B1

Biotech4

United States3

United Kingdom1

4 in this selection

Jul 22

Crystalys Therapeutics develops dotinurad, an oral URAT1 inhibitor for treating gout

$130MSeries B

Role not disclosed

Jun 24

Develops antibody therapies to prevent seasonal influenza in high-risk and immunocompromised patients

$115MSeries A

Role not disclosed

Feb 18

Develops novel therapies to reduce the burden of neurodegenerative diseases

$175MSeries A

Role not disclosed

Jan 14

Develops bispecific antibody CLD-423 for inflammatory bowel disease

$37.5MSeries A1

Role not disclosed